Prognostic significance of Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in ovarian cancer

Journal of Nippon Medical School

Volumn 71, Issue 6, 2004, Pages 384-391

  Mita, Shunji ^a   Nakai, Akihito ^a   Maeda, Shotaro ^a   Takeshita, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Ki 67 antigen; MIB 1 monoclonal antibody; Ovarian cancer; Prognosis

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MITOSIS INDEX; OVARY CANCER; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; ROC CURVE;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 12444346877     PISSN: 13454676     EISSN: None     Source Type: Journal    
DOI: 10.1272/jnms.71.384     Document Type: Article

References (27)

1. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A: National survey of ovarian carcinoma. Cancer 1993; 72: 3007-3011.
2. Kerns BJ, Jordan PA, Fareman LL, Berchuck A, Bast RC, Layfield LJ: Determination of Proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994; 101: 192-197.
3. Marx D, Meden H, Brune T, Kron M, Korabiowsa M, Kuhn W, Schauer A: Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res 1997; 17: 775-780.
4. Johannes G, Hilmar L, Heinz B, Hans HW, Ulrich S, Harald S: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
5. Giorgio C, Michael B, Goran K, Michael D, Carsten S, Jurgen G, Johannes G: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formarin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
6. Key G, Becker MHG, Duchrow M, Schinter C, Gerdes J: New Ki-67 equivalent murine monoclonal antibodies (MIB1-3) prepared against recombinant parts of the Ki-67 antigen. Anal Cell Pathol 1992; 4: 181.
7. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
8. Schwartz BR, Pinkus G, Bacus S, Toder M, Weinberg DS: Cell proliferation in non-Hodgkins lymphoma. Am J Pathol 1989; 134: 327-336.
9. Gatter KC, Dunnill MS, Gerdes J, Stein H, Mayson DY: New approach to assessing lung tumors in man. J Clin Pathol 1986; 39: 590-593.
10. Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells. Am J Surg Pathol 1986; 10: 611-617.
11. Benner SE, Clark GM, McGuire WL: Steroid receptors, cellular kinetics and lymph node status as prognostic indicators of breast cancer. Am J Med Sci 1988; 296: 59-66.
12. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, Yamanami H, Komatsu S, Horikoshi A: Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 2000; 17: 42-48.
13. Gerdes J, Becker MHG, Key G, Cattoretti G: Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1992; 168: 85-87.
14. Gioele G, Andrea C, Gaia G, Michele DN, Daniela S, Guendarina L, Graziella B: Ki67 Antigen immunostaining (MIB1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56: 169-174.
15. Helga BS, Ole E, Lars AA: Identification of high-risk patients by assessment of nuclear Ki-67 Expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998; 4: 2779-2785.
16. Viale G, Maisonneuve P, Bonoldi E, Bacco AD, Bevilacqua P, Panizzoni GA, Radaelli U, Gasparini G: The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Anal of Oncol 1997; 8: 469-476.
17. Hitchcock CL: Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin Pathol 1991; 96: 444-446.
18. Brown DC, Gatter KC: Monoclonal antibody Ki-67, its use in histopathology. Histopathology 1990; 17: 489-503.
19. Yaziji H, Gown AM: Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol 2001; 20: 64-78.
20. Elias LM: Cell proliferation indexes, a biomarker in solid tumors. Biotech Histochem 1997; 72: 78-85.
21. Isola J, Kallioniemi OP, Korte JM, Wahistrom T, Aine R, Helle M, Helin H: Steroid receptor and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990; 162: 295-301.
22. Huettner PC, Weinberg DS, Lage JN: Assessment of proliferativr activity in ovarian neoplasms by flow and static cytometry. Am J Pathol 1992; 141: 699-706.
23. Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS, Keeney GL, Roche PC: Proliferating cell nuclear antigen in epithelial ovarian cancer: Relation to results of second-look laparotomy and survival. Gynecol Oncol 1992; 47: 191-195.
24. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002; 100: 281-287.
25. Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC Jr, Kinney RB, Berchuck A: Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1993; 99: 736-746.
26. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K: Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 1994; 14: 603-608.
27. Charles EM: Basic principles of ROC analysis. Seminars in Nuclear Medicine 1978; 8: 283-298.